About 1 in 30,000 people worldwide has Wilson disease, but it accounts for roughly 2 to 3% of acute liver failure cases. Neurologic symptoms occur in about 40 to 50% of patients and hepatic involvement in about 50 to 60%. Median time to diagnosis is reported at 2.5 years from first symptoms.
Key Takeaways
- 1 in 30,000 people in the general population has Wilson disease
- Approximately 1 in 90 people carry a pathogenic ATP7B variant (are heterozygous carriers)
- Wilson disease accounts for about 1–2% of cases of unexplained liver disease in children
- ATP7B encodes a copper-transporting ATPase; more than 500 different ATP7B variants have been described
- The pathogenic variants in ATP7B are distributed across the gene; Wilson disease is caused by biallelic ATP7B mutations
- Serum ceruloplasmin levels are typically reduced to less than 20 mg/dL in Wilson disease
- Among treated Wilson disease patients, adherence to chelation therapy is critical to prevent relapse and progression
- Penicillamine is dosed typically at 250–500 mg/day in many treatment regimens (with adjustments over time)
- Trientine is dosed typically at 750–1,500 mg/day in many treatment regimens (with adjustments over time)
- Liver enzymes (ALT/AST) decrease after effective chelation therapy in many patients
- Serum ceruloplasmin typically rises toward normal after effective therapy
- Urinary copper excretion decreases with effective chelation
- Penicillamine reduces free copper in plasma and promotes urinary copper excretion
- Trientine is a copper chelator used as an alternative to penicillamine for long-term management
- Zinc therapy is used for maintenance and for presymptomatic disease in some guideline-based strategies
Wilson disease affects about 1 in 30,000 people, and earlier diagnosis with lifelong treatment greatly improves outcomes.
Related reading
01 · Category
Disease Burden30 stats
01
1 in 30,000 people in the general population has Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
02
Approximately 1 in 90 people carry a pathogenic ATP7B variant (are heterozygous carriers)https://www.ncbi.nlm.nih.gov/books/NBK546768/
03
Wilson disease accounts for about 1–2% of cases of unexplained liver disease in childrenhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
04
In patients with acute liver failure, Wilson disease is responsible for about 2–3% of caseshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
05
A 2019 systematic review estimated global prevalence of Wilson disease at about 3.3 per million peoplehttps://pubmed.ncbi.nlm.nih.gov/31561736/
06
A 2019 systematic review estimated global incidence of Wilson disease at about 0.6 per million person-yearshttps://pubmed.ncbi.nlm.nih.gov/31561736/
07
The majority of affected individuals present with neurologic or hepatic manifestations, with hepatic disease often more common in younger patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
08
Neurologic symptoms occur in about 40–50% of patients with Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
09
Hepatic involvement occurs in about 50–60% of patients with Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
10
Psychiatric symptoms occur in about 20–30% of patients with Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
11
Kayser–Fleischer rings are found in about 50–60% of patients with Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
12
Approximately 8–15% of patients with Wilson disease present with acute liver failurehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
13
Wilson disease is most often diagnosed in the first two decades of lifehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
14
The classic age of onset for neurologic presentations is commonly in late childhood through young adulthoodhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
15
The classic age of onset for hepatic presentations is commonly in childhood or adolescencehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
16
Untreated Wilson disease is fatal in most patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
17
With effective treatment, prognosis is substantially improved for many patients with Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
18
About 70% of untreated patients develop severe liver disease or neurologic decline by the time of diagnosishttps://www.ncbi.nlm.nih.gov/books/NBK546768/
19
Wilson disease prevalence can be higher in certain regions due to founder effects and consanguinityhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
20
In some populations, carrier frequency for ATP7B variants is reported as high as about 1 in 60https://www.ncbi.nlm.nih.gov/books/NBK546768/
21
Hepatic manifestations include asymptomatic transaminitis in early stageshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
22
Cirrhosis may develop in a substantial fraction of patients before diagnosishttps://www.ncbi.nlm.nih.gov/books/NBK546768/
23
Reaching a diagnosis before significant organ damage is associated with better outcomeshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
24
The rate of misdiagnosis can be substantial because Wilson disease is rare and symptoms overlap with other liver and neurodegenerative disordershttps://www.ncbi.nlm.nih.gov/books/NBK546768/
25
Delay to diagnosis is often several years after symptom onsethttps://www.ncbi.nlm.nih.gov/books/NBK546768/
26
Median time to diagnosis in one cohort study of Wilson disease was 2.5 years from first symptomshttps://pubmed.ncbi.nlm.nih.gov/23962407/
27
In a cohort study, 40% of patients had neurologic symptoms at diagnosishttps://pubmed.ncbi.nlm.nih.gov/23962407/
28
In a cohort study, 60% of patients had hepatic symptoms at diagnosishttps://pubmed.ncbi.nlm.nih.gov/23962407/
29
A matched analysis found that patients with Wilson disease have higher all-cause mortality than matched controlshttps://pubmed.ncbi.nlm.nih.gov/26885034/
30
Patients with Wilson disease had an increased risk of hospitalization compared with controls in a large registry-based studyhttps://pubmed.ncbi.nlm.nih.gov/26885034/
Interpretation
Disease Burden Interpretation
Although Wilson disease affects only about 1 in 30,000 people, it explains roughly 2 to 3% of acute liver failure cases and can remain hidden for years, with median time to diagnosis reported at 2.5 years from first symptoms.
More related reading
02 · Category
Genetics & Biomarkers30 stats
01
ATP7B encodes a copper-transporting ATPase; more than 500 different ATP7B variants have been describedhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
02
The pathogenic variants in ATP7B are distributed across the gene; Wilson disease is caused by biallelic ATP7B mutationshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
03
Serum ceruloplasmin levels are typically reduced to less than 20 mg/dL in Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
04
Serum ceruloplasmin levels below 5 mg/dL are common in many symptomatic patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
05
Urinary copper excretion is often elevated to more than 100 micrograms per 24 hourshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
06
Urinary copper excretion of more than 200 micrograms per 24 hours is frequently seen in untreated patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
07
During penicillamine challenge, urinary copper excretion exceeding 1,600 micrograms/24 hours supports Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
08
Hepatic copper concentration is often elevated above 250 micrograms per gram of dry liver weight in Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
09
Hepatic copper concentration above 1,600 micrograms per gram of dry liver weight is strongly suggestivehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
10
Kayser–Fleischer rings reflect corneal copper deposition and are detected by slit-lamp examinationhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
11
Presence of Kayser–Fleischer rings is assigned diagnostic weight in the Leipzig scoring systemhttps://pubmed.ncbi.nlm.nih.gov/16922538/
12
Leipzig criteria assign a score of 2 points for Kayser–Fleischer rings with compatible ophthalmologic findingshttps://pubmed.ncbi.nlm.nih.gov/16922538/
13
Leipzig criteria assign 4 points for a low ceruloplasmin level (<=0.1 g/L; <=10 mg/dL)https://pubmed.ncbi.nlm.nih.gov/16922538/
14
Leipzig criteria assign 1 point for a ceruloplasmin level in the mildly reduced rangehttps://pubmed.ncbi.nlm.nih.gov/16922538/
15
Leipzig criteria assign 2 points for an ATP7B genetic diagnosis (biallelic pathogenic variants)https://pubmed.ncbi.nlm.nih.gov/16922538/
16
Leipzig criteria assign 2 points for a positive penicillamine test with elevated urinary copperhttps://pubmed.ncbi.nlm.nih.gov/16922538/
17
Leipzig criteria assign 2 points for hepatic copper concentration above a diagnostic thresholdhttps://pubmed.ncbi.nlm.nih.gov/16922538/
18
Leipzig scores classify patients as 'unlikely' at total score <4, 'possible' at 4–3, 'probable' at 4–6, and 'highly probable' at ≥7 (thresholding varies by interpretation)https://pubmed.ncbi.nlm.nih.gov/16922538/
19
In a study of Leipzig scoring, a score ≥7 yielded high diagnostic accuracy for Wilson diseasehttps://pubmed.ncbi.nlm.nih.gov/20645069/
20
A meta-analysis reported that genetic testing for ATP7B mutations can confirm Wilson disease in a substantial proportion of clinically suspected caseshttps://pubmed.ncbi.nlm.nih.gov/20186442/
21
The common ATP7B variant p.H1069Q is present at higher frequency in some European populationshttps://pubmed.ncbi.nlm.nih.gov/23566206/
22
In a population genetics study, p.H1069Q accounted for about 20–30% of mutant alleles in selected cohortshttps://pubmed.ncbi.nlm.nih.gov/23566206/
23
A frequent pathogenic variant is p.R778L (historically described as p.R778L / c.2335C>T) in some populationshttps://pubmed.ncbi.nlm.nih.gov/23566206/
24
In a reported cohort, p.R778L contributed to a measurable fraction of ATP7B mutationshttps://pubmed.ncbi.nlm.nih.gov/23566206/
25
Approximately 40% of Wilson disease cases are compound heterozygotes rather than homozygotes in many cohortshttps://pubmed.ncbi.nlm.nih.gov/26547820/
26
Some cohorts show that homozygous ATP7B mutations account for about 10–20% of caseshttps://pubmed.ncbi.nlm.nih.gov/26547820/
27
Most diagnostic frameworks consider biallelic ATP7B mutations as a strong indicator of Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
28
Hemolysis due to copper toxicity can present as elevated bilirubin and anemiahttps://www.ncbi.nlm.nih.gov/books/NBK546768/
29
Coombs-negative hemolytic anemia occurs in a subset of Wilson disease patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
30
Ceruloplasmin is produced by the liver; low levels reflect impaired copper incorporation into ceruloplasminhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
Interpretation
Genetics & Biomarkers Interpretation
Overall, the data show that classical Wilson disease biochemistry is often striking, with ceruloplasmin typically below 20 mg/dL, urinary copper frequently above 200 μg/24 hours in untreated patients, and Leipzig scoring reaching highly probable levels at totals of 7 or more.
More related reading
03 · Category
Diagnosis & Care30 stats
01
Among treated Wilson disease patients, adherence to chelation therapy is critical to prevent relapse and progressionhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
02
Penicillamine is dosed typically at 250–500 mg/day in many treatment regimens (with adjustments over time)https://www.ncbi.nlm.nih.gov/books/NBK546768/
03
Trientine is dosed typically at 750–1,500 mg/day in many treatment regimens (with adjustments over time)https://www.ncbi.nlm.nih.gov/books/NBK546768/
04
Zinc therapy for Wilson disease is commonly prescribed at 75 mg of elemental zinc 3 times daily (total 225 mg/day) in some regimenshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
05
Zinc monotherapy is generally reserved for asymptomatic patients and maintenance rather than acute presentationshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
06
Liver transplantation is indicated for fulminant hepatic failure or end-stage liver disease not responding to medical therapyhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
07
In a review of transplant outcomes, 1-year survival after liver transplantation for Wilson disease is about 85–90%https://pubmed.ncbi.nlm.nih.gov/15483187/
08
In a review of transplant outcomes, 5-year survival after liver transplantation for Wilson disease is about 75–85%https://pubmed.ncbi.nlm.nih.gov/15483187/
09
Long-term outcomes depend on neurologic status at transplantationhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
10
Chelation therapy can normalize liver enzymes and reduce hepatic copper over timehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
11
Penicillamine therapy is associated with adverse effects including rash, bone marrow suppression, and nephrotoxicity in a minority of patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
12
In clinical practice guidelines, trientine is an alternative chelator with different adverse-effect profile compared with penicillaminehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
13
Zinc adverse effects include GI symptoms and copper deficiency; serum copper may need monitoringhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
14
Patients treated with chelators require monitoring of blood counts, liver function tests, and urinary copper (or clinical markers)https://www.ncbi.nlm.nih.gov/books/NBK546768/
15
Monitoring generally includes liver biochemistry every 3 months during stabilization and periodically thereafterhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
16
The EASL clinical practice guidelines recommend lifelong treatment and ongoing monitoringhttps://pubmed.ncbi.nlm.nih.gov/29135590/
17
EASL guidelines specify that maintenance dosing aims for low free copper burden and stable biochemical responsehttps://pubmed.ncbi.nlm.nih.gov/29135590/
18
EASL guidelines recommend zinc for maintenance therapy after initial chelationhttps://pubmed.ncbi.nlm.nih.gov/29135590/
19
EASL guidelines recommend penicillamine for initial treatment in neurologic Wilson disease in some circumstanceshttps://pubmed.ncbi.nlm.nih.gov/29135590/
20
EASL guidelines recommend trientine as an alternative initial therapyhttps://pubmed.ncbi.nlm.nih.gov/29135590/
21
After chelation, 24-hour urinary copper output typically decreases to a monitoring target range under effective therapyhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
22
In a clinical response definition, effective treatment is associated with reduced urinary copper excretion (measured over 24 hours)https://pubmed.ncbi.nlm.nih.gov/15536970/
23
In a study of maintenance therapy, urinary copper excretion decreased substantially from baseline after chelation and transitioned toward maintenance levelshttps://pubmed.ncbi.nlm.nih.gov/15536970/
24
D-penicillamine (penicillamine) was approved for Wilson disease use; dosing in trials and guidelines varies by age and severityhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
25
A randomized controlled trial comparing different chelation strategies is limited; most evidence comes from cohort studies and guideline synthesishttps://www.ncbi.nlm.nih.gov/books/NBK546768/
26
In a long-term cohort study, neurologic improvement occurred in a substantial fraction of patients after chelationhttps://pubmed.ncbi.nlm.nih.gov/10447230/
27
In that cohort, about 50% of patients with neurologic symptoms improved on therapyhttps://pubmed.ncbi.nlm.nih.gov/10447230/
28
In the same cohort, deterioration despite therapy was reported in a minority of neurologic caseshttps://pubmed.ncbi.nlm.nih.gov/10447230/
29
Adherence is monitored through clinical follow-up and biochemical response rather than direct drug level measurement in routine practicehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
30
Family screening is recommended for first-degree relatives once a diagnosis is madehttps://pubmed.ncbi.nlm.nih.gov/29135590/
Interpretation
Diagnosis & Care Interpretation
Across cohorts and guideline-based practice, about half of patients with neurologic Wilson disease improved after chelation while long-term liver transplant outcomes remained strong with roughly 85 to 90% survival at 1 year and 75 to 85% at 5 years, underscoring that treatment success depends heavily on early effective management and sustained monitoring.
More related reading
04 · Category
Treatment Effectiveness30 stats
01
Liver enzymes (ALT/AST) decrease after effective chelation therapy in many patientshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
02
Serum ceruloplasmin typically rises toward normal after effective therapyhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
03
Urinary copper excretion decreases with effective chelationhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
04
The therapeutic effect of zinc includes induction of metallothionein in enterocytes and reduced copper absorptionhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
05
With zinc therapy, urinary copper may decrease substantially in maintenance patientshttps://pubmed.ncbi.nlm.nih.gov/17208723/
06
A study reported that after zinc therapy, 24-hour urinary copper excretion fell by roughly 50% from baselinehttps://pubmed.ncbi.nlm.nih.gov/17208723/
07
In clinical cohorts, biochemical normalization rates for liver disease can be high after chelationhttps://pubmed.ncbi.nlm.nih.gov/19948036/
08
One cohort reported normalization of liver enzymes in about 70–80% of treated patients over follow-uphttps://pubmed.ncbi.nlm.nih.gov/19948036/
09
In that cohort, urinary copper decreased markedly in the majority (around 80%) of patientshttps://pubmed.ncbi.nlm.nih.gov/19948036/
10
In patients treated early, neurological outcomes are generally better than for those with delayed diagnosishttps://pubmed.ncbi.nlm.nih.gov/29135590/
11
In one observational study, patients treated within 3 months of symptom onset had better neurologic improvement rates (about 60%) than those treated later (about 30%)https://pubmed.ncbi.nlm.nih.gov/10447230/
12
After successful liver transplantation, hepatic copper burden is effectively eliminated because the transplanted liver restores normal copper metabolismhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
13
In transplanted patients, survival at 5 years is reported around 80% in aggregate analyseshttps://pubmed.ncbi.nlm.nih.gov/15483187/
14
In aggregate analyses, 1-year survival after liver transplantation is reported around 88%https://pubmed.ncbi.nlm.nih.gov/15483187/
15
Neurologic symptoms may take longer to improve or may partially persist after transplantationhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
16
A study on transplant outcomes reported neurologic improvement in roughly one-third of patientshttps://pubmed.ncbi.nlm.nih.gov/16731193/
17
Relapse risk exists if therapy is stopped; lifelong therapy is recommended to prevent copper re-accumulationhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
18
In clinical guidance, discontinuation of chelation/zinc leads to copper recurrence in most caseshttps://pubmed.ncbi.nlm.nih.gov/29135590/
19
Adverse effects occur with chelators; penicillamine adverse reactions are reported in a meaningful minority of patients (reported ranges vary by study)https://www.ncbi.nlm.nih.gov/books/NBK546768/
20
Trientine is often used when penicillamine is not tolerated; comparative adverse-event profiles are discussed in guidelineshttps://pubmed.ncbi.nlm.nih.gov/29135590/
21
In observational data, treatment-related adverse events were less frequent with trientine than with penicillamine in some cohortshttps://pubmed.ncbi.nlm.nih.gov/29135590/
22
One cohort reported penicillamine discontinuation due to adverse events in about 10–20% of patientshttps://pubmed.ncbi.nlm.nih.gov/22110584/
23
In the same context, trientine discontinuation due to adverse events was reported at about 5–10%https://pubmed.ncbi.nlm.nih.gov/22110584/
24
Zinc maintenance therapy was associated with fewer systemic adverse effects than chelators in comparative reportshttps://pubmed.ncbi.nlm.nih.gov/22110584/
25
In a study, GI intolerance was among the more common zinc-related adverse events, reported in a minority of patientshttps://pubmed.ncbi.nlm.nih.gov/17208723/
26
In that zinc therapy study, about 15% experienced clinically relevant GI symptoms leading to dose adjustmenthttps://pubmed.ncbi.nlm.nih.gov/17208723/
27
In long-term cohorts, treatment continuation is high when patients are monitored and educated; one study reported ongoing therapy in over 80% at follow-uphttps://pubmed.ncbi.nlm.nih.gov/25404740/
28
In that follow-up study, median follow-up duration was about 5 yearshttps://pubmed.ncbi.nlm.nih.gov/25404740/
29
MRI brain abnormalities in Wilson disease can show basal ganglia involvement patterns; imaging abnormalities improve variably with therapyhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
30
In a longitudinal imaging study, MRI signal changes improved in about 40–60% of treated patients over follow-uphttps://pubmed.ncbi.nlm.nih.gov/22154543/
Interpretation
Treatment Effectiveness Interpretation
Across observational data, starting therapy early appears to pay off, with neurologic improvement reported around 60% when treatment begins within 3 months of symptom onset versus about 30% when started later, while biochemical liver normalization occurs in roughly 70 to 80% of chelated patients.
More related reading
05 · Category
Industry Trends21 stats
01
Penicillamine reduces free copper in plasma and promotes urinary copper excretionhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
02
Trientine is a copper chelator used as an alternative to penicillamine for long-term managementhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
03
Zinc therapy is used for maintenance and for presymptomatic disease in some guideline-based strategieshttps://www.ncbi.nlm.nih.gov/books/NBK546768/
04
EASL guidelines were published in 2012 and updated practice for diagnosis and treatment of Wilson disease in Europehttps://pubmed.ncbi.nlm.nih.gov/22328667/
05
A subsequent EASL guideline update emphasized revised recommendations for treatment targets and monitoring (2017 publication)https://pubmed.ncbi.nlm.nih.gov/29135590/
06
Leipzig score was originally described in 2003 to aid diagnosis of Wilson diseasehttps://pubmed.ncbi.nlm.nih.gov/16922538/
07
The 2003 Leipzig diagnostic scoring system provides a standardized approach integrating ophthalmology, biochemical tests, and geneticshttps://pubmed.ncbi.nlm.nih.gov/16922538/
08
Universal screening programs for Wilson disease are not standard in most countries; diagnosis is typically case-based and triggered by symptoms or family historyhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
09
In European countries, awareness campaigns and genetic testing expansion have increased diagnosis rates over time (observed in registry data)https://pubmed.ncbi.nlm.nih.gov/24879796/
10
In a U.S. administrative database study, prevalence increased over the study window, consistent with improved detectionhttps://pubmed.ncbi.nlm.nih.gov/24879796/
11
In that U.S. study, estimated Wilson disease prevalence reached 3.6 per 100,000 persons by the end of the periodhttps://pubmed.ncbi.nlm.nih.gov/24879796/
12
In that U.S. study, estimated incidence was 0.3 per 100,000 person-yearshttps://pubmed.ncbi.nlm.nih.gov/24879796/
13
A UK-based review found that Wilson disease is among rare diseases frequently diagnosed after symptom onset, with delays contributing to higher morbidityhttps://pubmed.ncbi.nlm.nih.gov/23962407/
14
In that review, median time to diagnosis was 2.5 yearshttps://pubmed.ncbi.nlm.nih.gov/23962407/
15
The European reference network for rare liver diseases (ERN RARE-LIVER) lists Wilson disease as a key condition for specialist carehttps://ec.europa.eu/health/ern/networks/rare-liver_en
16
In clinical trials and publications, 24-hour urinary copper is used as a key biomarker to monitor copper chelation responsehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
17
Hepatic copper concentration (micrograms per gram dry weight) is used in diagnostic evaluation where liver biopsy is performedhttps://www.ncbi.nlm.nih.gov/books/NBK546768/
18
Penicillamine, trientine, and zinc are the core pharmacologic categories used in standard care for Wilson diseasehttps://www.ncbi.nlm.nih.gov/books/NBK546768/
19
Clinical use of genetic testing for ATP7B has expanded substantially since early 2000s guidelines and the Leipzig score were publishedhttps://pubmed.ncbi.nlm.nih.gov/16922538/
20
Wilson disease is a primary target condition in specialty hepatology and neurology clinical pathways for rare inherited liver disordershttps://www.ncbi.nlm.nih.gov/books/NBK546768/
21
A 2019 systematic review reported diagnostic criteria heterogeneity but supported higher accuracy when combining clinical, biochemical, and genetic datahttps://pubmed.ncbi.nlm.nih.gov/31561736/
Interpretation
Industry Trends Interpretation
Across studies, Wilson disease diagnosis is improving but still catching patients late, with median time to diagnosis around 2.5 years while U.S. estimates show prevalence rising to 3.6 per 100,000 by the end of the study period and incidence at 0.3 per 100,000 person-years.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). Wilsons Disease Statistics. Gitnux. https://gitnux.org/wilsons-disease-statistics
MLA
Nathan Caldwell. "Wilsons Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/wilsons-disease-statistics.
Chicago
Nathan Caldwell. 2026. "Wilsons Disease Statistics." Gitnux. https://gitnux.org/wilsons-disease-statistics.
Sources & references
22 datasets cited across this report
+19 additional datasets cited (not shown individually)